Exelixis had its Relative Strength (RS) Rating upgraded from 77 to 81 Friday.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD's proprietary rating measures price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Exelixis is building a consolidation with a 27.90 buy point. See if it can break out in volume at least 40% higher than normal.
Top and bottom line growth moved higher last quarter. Earnings were up -14%, compared to -30% in the prior report. Revenue increased from 5% to 8%. The next quarterly results are expected on or around Oct. 30.
Exelixis earns the No. 10 rank among its peers in the Medical-Biomed/Biotech industry group. Emergent Biosolutions, Genmab and Horizon Pharma are among the top 5 highly rated stocks within the group.
